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Several clinical trials to establish standard treatment modality for ovarian cancers included a high abundance of
patients with serous histologic tumors, which were quite sensitive to platinum-based chemotherapy. On the other
hand, ovarian tumor with rare histologic subtypes such as clear cell or mucinous tumors have been recognized to
show chemo-resistant phenotype, leading to poorer prognosis. Especially, clear cell carcinoma of the ovary (CCC) is
a distinctive tumor, deriving from endometriosis or clear cell adenofibroma, and response rate to platinum-based
therapy is extremely low. It was implied that complete surgical staging enabled us to distinguish a high risk group
of recurrence in CCC patients whose disease was confined to the ovary (pT1M0); however, complete surgical
staging procedures could not lead to improved survival. Moreover, the status of peritoneal cytology was recognized
as an independent prognostic factor in early-staged CCC patients, even after complete surgical staging. In
advanced cases with CCC, the patients with no residual tumor had significantly better survival than those with the
tumor less than 1 cm or those with tumor diameter more than 1 cm. Therefore, the importance of achieving no
macroscopic residual disease at primary surgery is so important compared with other histologic subtypes. On the
other hand, many studies have shown that conventional platinum-based chemotherapy regimens yielded a poorer
prognosis in patients with CCC than in patients with serous subtypes. The response rate by paclitaxel plus
carboplatin (TC) was slightly higher, ranging from 22% to 56%, which was not satisfactory enough. Another
regimen for CCC tumors is now being explored: irinotecan plus cisplatin, and molecular targeting agents. In this
review article, we discuss the surgical issues for early-staged and advanced CCC including possibility of
fertility-sparing surgery, and the chemotherapy for CCC disease.
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Clear cell adenocarcinoma (CCC) is a distinct entity
from other epithelial ovarian carcinomas (EOC). CCC is
thought to arise from endometriosis or clear cell adeno-
fibroma, however, the origin of serous cyst adenocarcin-
oma (SCA) is thought to be Mullerian epithelium
derived from either ovarian surface epithelium or fallo-
pian tube (endosalpingiosis). CCC has specific biological
and clinical behavior, compared with other histological
types. However, in the studies used as evidence for
recommended treatment as standard treatment of EOC,
most of the enrolled patients were not clear cell* Correspondence: mastkn@ndmc.ac.jp
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reproduction in any medium, provided the orhistology, and these study results do not provide a scien-
tific rationale for CCC. In this review, we summarize the
treatment of CCC.
Surgical treatment
The standard surgical treatment of patients with EOC is
based on hysterectomy, bilateral salpingo-oophorectomy
and partial omentectomy with peritoneal sampling and
lymphadenectomy, and cytoreductive surgery is added
especially for advanced cases. The surgical treatment of
CCC is usually determined based on the guideline of
EOC. In this section, we summarize the surgical treat-
ment of CCC patients.
Surgical staging
It has been reported that the incidence of lymph node
metastasis in stage I (pT1) EOC was approximately 5-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Rates of lymph node metastasis in early-staged
clear cell carcinoma and serous adenocarcinoma
author year number of
patients
pT stage metastatic rate
clear cell carcinoma
Di Re[2] 1989 11 pT1 9% (1/11)
Petru[3] 1994 2 pT1 0% (0/2)
Onda[4] 1996 16 pT1/2 31% (5/16)
Baiocchi[5] 1998 21 pT1 5% (1/21)
Suzuki[6] 2000 9 pT1 11% (1/9)
Sakuragi[7] 2000 23 pT1/2 17% (4/23)
Negishi[8] 2004 46 pT1 12% (5/42)
pT2 75% (3/4)
Takano[9] 2006 173 pT1a 9% (3/36)
pT1c 7% (7/99)
pT2 13%(5/38)
Harter[10] 2007 7 pT1 0% (0/7)
Desteli[11] 2010 4 pT1 0% (0/4)
Nomura[12] 2010 36 pT1/2 6% (2/36)
Subtotal 348 11%(37/348)
Serous cystadenocarcinoma
Di Re[2] 1989 40 pT1 28% (11/40)
Petru[3] 1994 21 pT1 38% (8/21)
Onda[4] 1996 21 pT1/2 33% (7/21)
Baiocchi[5] 1998 106 pT1 26% (27/106)
Suzuki[6] 2000 13 pT1 31% (4/13)
Sakuragi[7] 2000 25 pT1/2 8% (2/25)
Morice[13] 2003 26 pT1 31% (8/26)
Negishi[8] 2004 35 pT1 4% (1/24)
pT2 36% (4/11)
Harter[10] 2007 13 pT1 15% (2/13)
Desteli[11] 2010 7 pT1 14% (1/7)
Nomura[12] 2010 12 pT1/2 50% (6/12)
Subtotal 319 25%(81/319)
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CCC and serous cystadenocarcinoma (SAC) were sum-
marized in Table 1 [2-14]. From the results investigating
a large number of CCC cases, retroperitoneal lymph
node metastasis was observed in 9% in pTIa tumors, 7%
in pTIc tumors, and 13% in pT2 tumors in CCC, which
suggested that incidence of lymph node metastasis in
CCC was lower than that of SAC [9]. Based on the sub-
total of reported cases with pT1 and pT2 tumors, ap-
proximately one half incidence of lymph node metastasis
in CCC in comparison with SAC was confirmed: 11% in
CCC, and 25% in SAC.
Lymphadenectomy is so important to detect meta-
static lymph nodes, as the patients with positive lymph
nodes had poorer prognosis. However, the role of lym-
phadenectomy remains unclear based on the therapeuticaspect. Several authors reported that lymph node metas-
tasis is independent prognostic factor for CCC [7,8,15].
Magazzino et al. analyzed 240 CCC retrospectively and
reported as followed [15]: (1) Of 240 cases, 47.9% had
lymphadenectomy and most of cases received platinum
based chemotherapy after primary surgery. (2) The cases
who received lymphadenectomy had longer progression-
free survival (PFS) than the cases who had no lymphade-
nectomy in stage I/II, III/IV and all stage (p = 0.0258,
p = 0.00337, p = 0.0001). (3) In advanced cases, lympha-
denectomy prolonged the overall survival (OS). (4) In
CCC, lymphadenectomy and clinical stage are independ-
ent prognostic factors by multivariate analysis. However,
we reported that pN status showed only a marginal sig-
nificance upon PFS and no significance upon OS based
on the analysis of 199 CCC [16]. Other reports failed to
show the usefulness of lymphadenectomy as prognostic
factor [17,18]. Further examination will be required to
confirm the role of lymphadenectomy for CCC.
In our studies, multivariate analysis revealed that peri-
toneal cytology status was independent prognostic factor
for PFS (p = 0.04), but not for OS, and in addition, com-
pletion of surgical staging procedures was not a prog-
nostic factor [16]. Higashi et al. analyzed 224 CCC
patients with stage I and reported as followed [19]: (1)
there was no significant difference in both OS and PFS
of CCC between stage IA and IC (intraoperative capsule
rupture), and the 5-year OS rate of stage IC(intraopera-
tive capsule rupture) CCC patients was comparable to
those with the non-CCC. (2) Stage IC CCC patients ex-
cept for IC (intraoperative capsule rupture), such as
positive ascites/washing and capsule surface involve-
ment, had a poorer OS and PFS than those with IC
(intraoperative capsule rupture). The results suggested
stage I CCC cases other than intraoperative capsule rup-
ture were at a considerable risk for recurrence and
mortality.
Finally, the role of complete surgical staging still
remains unclear for CCC. Several reports demonstrated
that adjuvant chemotherapy had little impact on the sur-
vival of stage I CCC patients [16,20]. From these find-
ings, complete surgical staging procedures are required
at least to detect high-risk patients of recurrence; how-
ever, the extent of the surgery could not improve overall
survival of CCC.
Cytoreductive surgery
Optimally cytoreduced patients of EOC were reported to
show a significant survival benefit over those patients
who are suboptimally debulked, and there is a significant
survival advantage in patients who are able to be
debulked to less than 1 cm of residual disease. Hoskins
et al. reported that patients with clear cell and mucinous
histology had poor outcome even when they had small
Table 2 Relapse rates of clear cell carcinoma patients
who received FSS
stage author year number of patients relapse
Stage IA Kajiyama [23] 2008 4 0% (0/4)
Satoh [24] 2010 15 0% (0/15)
total 19 0% (0/19)
Stage IC Schilder [22] 2001 5 0% (0/5)
Kajiyama [23] 2008 6 17% (1/6)
Satoh [24] 2010 15 33% (5/15)
total 26 23% (6/26)
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reported that there is no significant prognostic difference
between the patients with the tumor diameter less than
1 cm and those with the tumor diameter more than
1 cm, and complete surgery is only the independent
prognostic factor [9]. Kennedy et al. reported that
among patients with advanced stage cancers (FIGO
stages III and IV), CCC patients were more often opti-
mally debulked than non-CCC patients (60% vs. 37%,
p = 0.033) [22]. From these findings, the goal of primary
surgical treatment for CCC may be complete resection.
Fertility-sparing surgery
Fertility-sparing surgery (FSS) for reproductive-age
patients with EOC has been adopted for stage IA and
non-clear cell histology grade 1 (G1)/grade2 (G2)
according to the 2007 guidelines of the American Col-
lege of Obstetrics and Gynecology (ACOG) and unilat-
eral stage I tumor without dense adhesions showing
favorable histology (ie, non-clear cell histology G1/G2)
according to the 2008 guidelines of the European Society
for Medical Oncology (ESMO). In Japan, stage IA tumor
or unilateral stage IC tumor on the basis of intraopera-
tive capsule rupture and favorable histology are candi-
date for FSS according to the 2010 guidelines of the
Japan Society of Gynecologic Oncology (JSGO). These 3
guidelines commonly eliminate CCC for the candidate
of FSS. In contrast, in the 2010 guidelines of the Na-
tional Comprehensive Cancer Network (NCCN), a stage
I patient with CCC is an acceptable candidate for FSS.
For the patients to receive FSS, randomized study can-
not be performed because of ethical aspect. In this re-
view, we summarize the FSS for CCC based on the
retrospective studies.
Schilder et al. demonstrated that no recurrence was
observed among 5 patients with stage IC CCC who
received FFS; however, the detail of stage or postopera-
tive chemotherapy was not recorded [23]. Kajiyama et al.
reported the clinical outcome of 10 patients with stage I
CCC treated with FSS (IA:4, IC(intraoperative capsule
rupture): 5, IC(positive for malignant ascites):1) and
demonstrated as follow [24]: (1) Among 10 patients, 9
patients received chemotherapy after surgery, (2) one pa-
tient with IC(positive for malignant ascites) who
received postoperative chemotherapy recurred. Sato
et al. reported 30 patients with stage I CCC who
received FFS and reported as follow [25]: (1) Among 15
IA cases, 9 cases received chemotherapy after surgery
and no one recurred, (2)Among 15 IC patients, 11
patients received chemotherapy after surgery, and 2
patients (IC(intraoperative capsule rupture):2) recurred
among 11 patients who received chemotherapy and 3
patients (IC(intraoperative capsule rupture):2, IC(posi-
tive for malignant ascites or surface capsuleinvolvement):1) recurred among 4 patients who did not
received chemotherapy. (3) Recurrent sites are residual
ovary (n = 3), lymph node (n = 2), peritoneum (n = 2) and
liver (n = 1). (4) The 5-year survival rate is 93.3%. These
data are shown in Table 2.
We summarized Kajiyama’s and Sato’s reports in detail:
(1) Among 19 patients, 12 patients received postopera-
tive chemotherapy and no one recurred. (2) Among 21
IC patients, 17 patients received postoperative chemo-
therapy, and recurrent rate of IC(intraoperative capsule
rupture) and IC(positive for malignant ascites or surface
capsule involvement) are 25%(4/16) and 40%(2/5). (3)
Among 17 IC patients who received postoperative
chemotherapy, 3 (18%) patients recurred and among 4
IC patients who did not received chemotherapy, 3 (75%)
patients recurred.
Recently, Kajiyama et al. also analyzed the OS of 16
patients with stage I CCC who underwent FSS and com-
pared survival with 204 patients receiving radical sur-
gery, or 64 patients with non-CCC undergoing FSS and
demonstrated that patients with CCC who underwent
FSS did not show a poorer survival than non-CCC
patients who underwent FSS, or those at the corre-
sponding stage with no CCC [26].
From these findings, CCC IA patient may be candidate
for FFS and postoperative chemotherapy may be useful
for CCC IC patient who received FFS.Chemotherapeutic treatment
Clear cell carcinoma (CCC) is a quite unique ovarian
tumor showing resistance to platinum-based chemother-
apy. The effect of the gold standard therapy for ovarian
carcinomas, combination with paclitaxel and carboplatin
(TC), is not satisfactory for CCC. Irinotecan hydrochlor-
ide, a topoisomerase I inhibitor, is a candidate for the
treatment for CCC. Irinotecan combined with cisplatin
(CPT-P) has been recognized to have an activity no less
than TC for CCC. A world-wide prospective clinical
study to compare CPT-P and TC as the first-line chemo-
therapy for CCC, GCIG/JCOG (Gynecologic Cancer
Intergroup/Japanese Gynecologic Oncology Group)
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agents are evaluated for advanced or recurrent CCC. We
would discuss the chemotherapeutic regimens as pri-
mary or second-line therapy for CCC in this review.
Primary chemotherapy using cytotoxic agents
It has been implied that CCC of the ovary showed resist-
ance to conventional platinum-based chemotherapy [27-
29]. Recent studies have confirmed the evidence in the
analysis of patients with measurable CCC. Objective re-
sponse was observed in 11-27% with conventional plat-
inum-based regimen, whereas patients with serous
adenocarcinoma (SAC) subtype showed a significantly
higher response rate of 73-81% [30-32]. A report showed
survival benefit of conventional chemotherapy with
paclitaxel and platinum after complete surgery in CCC
patients [33]. However, the result from large series of
CCC patients treated with paclitaxel and platinum
showed no survival benefit compared with conventional
platinum-based chemotherapy in both early and
advanced cases [9]. The results suggested that TC ther-
apy, which is commonly used for ovarian carcinoma, is
not effective enough for CCC patients. Reported re-
sponse rates of primary therapy for CCC are summar-
ized in Table 3 [9,29-33].
Irinotecan hydrochloride, a semisynthetic derivative of
camptothecin, has additive and synergic effects in com-
bination with cisplatin in vitro [34,35]. The combination
therapy with irinotecan hydrochloride and cisplatin
(CPT-P) was reported to be effective for patients with
various solid tumors. Especially, a large clinical trial
revealed that CPT-P had significant activity for extensive
small-cell lung cancer [36]. Additionally, CPT-P had
been reported to be effective in first-line and second-line
chemotherapy for the treatment of CCC of ovary
[37,38]. A large retrospective analysis indicated that
CPT-P had a potential therapeutic effect at least no less
than TC therapy [39]. A phase II study (JGOG3014) toTable 3 Response rates of primary chemotherapy for
clear cell carcinoma





Goff [28] 1996 1/6, 17%
Sugiyama [29] 2000 3/27, 11%
Ho [30] 2004 4/15, 27%
Takano [9] 2006 5/30, 17%
Taxane-Platinum Enomoto [31] 2003 2/9, 22%
Ho [30] 2004 9/16, 56%
Utsunomiya [32] 2006 8/15, 53%
Takano [9] 2006 9/28, 32%
Irinotecan-cisplatin Takano [9] 2006 3/10, 30%compare CPT-P and TC for first-line treatment for CCC
was conducted. The study revealed that completion rate
of six cycles and five-year progression-free survival was
similar in both arms [40]. Interesting to note, in the
patients with residual tumor less than 2 cm, overall sur-
vival was marginally improved in CPT-P group in com-
parison with TC group (p = 0.056). Subsequently, a phase
III randomized study to compare CPT-P and TC as ad-
juvant chemotherapy for CCC is on-going (GCIG/
JGOG3017) [41]. The winner regimen will be the first
regimen for histologically individualized therapy for
ovarian cancers.
Another issue concerning chemotherapy for CCC is
adjuvant therapy for patients with stage I disease. CCC
is regarded as grade 3 tumor, and clinical guidelines rec-
ommend adjuvant chemotherapy for all patients with
CCC, even at stage Ia. A large retrospective analysis of
stage I CCC revealed that there were no statistical differ-
ences of progression-free survival (PFS) and overall sur-
vival (OS) between patients with chemotherapy and
without chemotherapy [16]. Also, multivariate analysis
showed that peritoneal cytology status (p = 0.02) and pT
status (p = 0.04) were independent prognostic factors for
PFS, however, adjuvant chemotherapy was not a prog-
nostic factor (p = 0.80). The results suggested adjuvant
chemotherapy had little impact upon survival of stage I
CCC patients. Further strategy, such as a molecular tar-
geting agent, is needed to improve survival of CCC, es-
pecially cases with positive peritoneal washing.
Second-line chemotherapy for CCC
In a large series of platinum-sensitive relapsed ovarian
tumors including all histological subtypes, overall re-
sponse was 54% of the patients treated with the conven-
tional platinum-based chemotherapy, and 66% of the
cases treated with paclitaxel plus platinum chemother-
apy [42]. In the platinum-resistant tumors, however, re-
sponse rate using anti-cancer agents usually range from
25 to 30% [43]. In the second-line or salvage settings,
the response rate for recurrent or refractory CCC was
extremely lower than that for other histological tumors:
even in the patients with platinum-sensitive CCC dis-
ease, the response rate reported was lower than 10%
[44,45]. So, we have summarized reported cases that
achieved objective response (Table 4) [30,33,44-48].
Recently, single agent gemcitabine could be a candi-
date for salvage therapy for CCC, as the authors sug-
gested [44,48]. Other regimens that showed objective
response included irinotecan/platinum, etoposide/platinum,
and paclitaxel/carboplatin; however, the efficacy was
limited with progression-free interval approximately
6 months. Despite importance of response, it would be
more important to monitor if adverse effects of chemo-
therapy worsen quality of life of the patients. Among
Table 4 Response rates of salvage chemotherapy for
recurrent or refractory clear cell carcinoma
regimen author year response/ number
of patients,
response rate
Megestrol acetate Walailak [45] 2001 2/10, 20%
Cyclopshosphamide+
cisplatin
Takano [46] 2008 1/9, 11%
Irinotecan+Platinum Sugiyama [29] 1998 1/3, 33%
Takano [46] 2008 2/15, 13%
Etoposide+Platinum Takano [46] 2008 2/13, 15%
Paclitaxel+Carboplatin Utsunomiya [32] 2006 3/13, 23%
Crotzer [43] 2007 2/7, 29%
Gemcitbine Crotzer [43] 2007 1/9, 11%
Yoshino [47] 2012 1/5, 20%
Docetaxel+Irinotecan Yoshino [47] 2012 1/11, 9%
Temsirolimus Takano [46] 2011 1/5, 20%
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14 months was obtained by Temsirolimus [47]. The
observed response duration was surprisingly longer than
those obtained by any cytotoxic agents so far with no
serious toxicities. The report encouraged us to investi-
gate another chemotherapeutic strategy for CCC.
From the reported cases, however, it could be con-
cluded that CCC is a potentially extremely chemo-resistant
tumor against cytotoxic agents, especially in recurrent or
refractory settings. Another strategy including molecular
targeting agents might be needed for the treatment of
these tumors.
Incorporation of molecular targeting agents for the
treatment of CCC
In the aspects of molecular characteristics as well as
clinical behavior, it is hypothesized that CCC belongs to
a different entity from other histological subtypes of
ovarian carcinoma. First of all, the incidences of p53 mu-
tation and p53 overexpression were much less frequent
in CCC than in other histologic types of epithelial ovar-
ian cancer [49,50]. On the other hand, mutation of p53
gene was quite frequent in serous subtype of ovarian
cancers, and most of the alterations were missense
mutations [51]. In addition to p53 status, CCC has a
quite unique expression pattern of several molecules.
Glutathione peroxidase 3 (GPX3) was found at levels
30-fold higher on average in CCC compared with the
other ovarian cancer subtypes through studies with
cDNA arrays and serial analysis of gene expression [52].
Elevated expression of GPX3 might contribute to che-
moresistance phenotype, which is often observed in the
patients with CCC. Another investigation using oligo-
nucleotide microarrays reported that glutaredoxin
(GLRX) and superoxide dismutase 2 (SOD2), in additionto GPX3, were highly expressed in clear cell type ovarian
cancer, suggesting that high levels of these proteins relat-
ing with antioxidant function render CCC to be more
resistant to chemotherapy [53,54].
Further, a report using oligonucleotide probe arrays
showed that a transcription factor, hepatocyte nuclear
factor-1 (HNF-1) was upregulated in CCC cell lines [55].
Overexpression of HNF-1 was confirmed by immunohis-
tological staining of clinical samples. Further, overex-
pression of HNF-1 was observed in the specimens of
borderline clear cell tumor and benign clear cell tumor
[56]. The expression of HNF-1 was detected in not only
atypical endometrial tissue, but also in endometriosis
with degenerative and regenerative changes, suggesting
that early differentiation into the clear cell lineage takes
place in the endometriotic epithelium, and HNF-1 con-
tributes to carcinogenesis of CCC.
Recently, immunohistochemical analysis showed that
hypoxia-inducible factor 1 alpha (HIF-1alpha) expression
levels were significantly higher in CCC than in other
histological types of ovarian cancers [57]. Upstream tar-
get of HIF-1alpha, mammalian target of rapamycin
(mTOR), was also reported to be up regulated in CCC
[58,59], which was selected for molecular target of CCC.
There are two international collaborating studies led
by Gynecologic Oncology Group (GOG) to evaluate effi-
cacy of molecular targeting agents for CCC of the ovary
[60,61]. It is true that there existed super-responders
against molecular targeting agents in the patients with
CCC. Consequently, further studies to evaluate these
new drugs should include biomarker analysis to predict
response or adverse effect for clinical application.
Conclusions
CCC has unique characteristics among ovarian cancers.
We have to deal with the tumor using completely differ-
ent techniques of treatment modality in terms with sur-
gery and chemotherapy. Especially, we have to focus on
histology-specific features of molecular pattern. We
hope the day will come when CCC tumors would be
easily handled by the selection of effective surgery and
chemotherapy including molecular targeting agents.
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